Phlox Therapeutics Secures New Funding to Advance RNA Therapies for Genetic Cardiomyopathies
Phlox Therapeutics raises 1.9M funding to develop RNA therapies for genetic laminopathies The investor syndicate includes ROM Utrecht Region, FIRST Fund, Amsterdam-UMC Ventures and UHSF Funds support preclinical development of Phox’s lead program Naarden, The Netherlands, 6 November 2024 – Phlox Therapeutics, a private biotechnology company focused on developing innovative RNA-based therapies for cardiomyopathies, […]
